drugset / Trial / NCT06849921
Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors
NaSequentialOpen-labelTreatment
Summary
This clinical trial aims to evaluate the efficacy and safety of CAR-T cell therapy in patients with relapsed/refractory hematologic malignancies.
Timeline
- Start
- 2024-11-07
- Primary completion
- 2030-12-30
- Completion
- 2030-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |